Drug Interactions between methotrexate and ruxolitinib topical
This report displays the potential drug interactions for the following 2 drugs:
- methotrexate
- ruxolitinib topical
Interactions between your drugs
methotrexate ruxolitinib topical
Applies to: methotrexate and ruxolitinib topical
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration of topical ruxolitinib with other Janus Kinase (JAK) inhibitors, biologic immunomodulators, or other potent immunosuppressants (e.g., cyclosporine, azathioprine) may potentiate the risk of infections as well lymphoma and other malignancies. Serious and sometimes fatal infections including bacterial, mycobacterial (e.g., tuberculosis), fungal, viral including viral reactivation, and other opportunistic infections have been reported in patients who have received oral ruxolitinib, including oral ruxolitinib for inflammatory conditions.
MANAGEMENT: The safety and efficacy of topical ruxolitinib in combination with immunosuppressive agents has not been evaluated. It is recommended that the concomitant use of topical ruxolitinib with other Janus Kinase (JAK) inhibitors, biologic immunomodulators, or other potent immunosuppressants (e.g., cyclosporine, azathioprine) should be avoided. Patients receiving topical ruxolitinib should be closely monitored for the development of signs and symptoms of infection during and after treatment, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. If a patient develops a serious infection, ruxolitinib topical therapy should be interrupted until the infection is controlled.
Drug and food interactions
ruxolitinib topical food
Applies to: ruxolitinib topical
Consumer information for this interaction is not currently available.
MONITOR CLOSELY: Smoking during treatment with topical ruxolitinib may increase the risk of major adverse cardiovascular events (MACE) and the risk of developing malignancies, including lymphomas. During clinical trials, patients who were current or past smokers and received oral Janus Kinase (JAK) inhibitors to treat inflammatory conditions had an additional increased risk of overall malignancies. Additionally, oral JAK inhibitors reportedly increase patients' risk of MACE, including cardiovascular death, myocardial infarction, and stroke, particularly in patients who are current or past smokers or patients with other cardiovascular risk factors.
MANAGEMENT: The potential risks and benefits of topical ruxolitinib should be carefully weighed prior to initiating therapy, particularly in patients with cardiovascular risk factors, as well as those with a history of malignancy, those who develop a malignancy while on treatment, and/or patients who are current or past smokers. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. The manufacturer recommends discontinuing topical ruxolitinib in patients who have experienced a myocardial infarction or stroke.
methotrexate food
Applies to: methotrexate
Caffeine may reduce the effectiveness of methotrexate in the treatment of arthritis. If you are receiving methotrexate for arthritis, you may want to limit your intake of caffeine-containing foods and medications. Check with your doctor or pharmacist if you have concerns or are uncertain what products may contain caffeine.
methotrexate food
Applies to: methotrexate
Methotrexate may cause liver problems, and using it with other medications that can also affect the liver such as ethanol (alcohol) may increase that risk. You should avoid or limit the use of alcohol while being treated with these medications. Call your doctor immediately if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. Talk to your doctor or pharmacist if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
methotrexate food
Applies to: methotrexate
Caffeine may reduce the effectiveness of methotrexate in the treatment of arthritis. If you are receiving methotrexate for arthritis, you may want to limit your intake of caffeine-containing foods and products. Contact your doctor if your symptoms worsen or your condition changes during treatment with these medications. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.